SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gene Voss who wrote (4795)1/20/1998 6:03:00 AM
From: BigKNY3  Read Replies (1) of 23519
 
Gene <<This entire discussion is much more pharmacologic and transcends ordinary urologic investigations.My main point is that these oral agents should be aggresively reviewed on a biochemical level not just whether or not an erection results in healthy men>>

Gene: I respect and appreciate your reply and agree with you.

I recommend reading the International Journal of Impotence Research article "Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treament of penile erectile dysfunction: (1996, 47-52) for a review of its pharmacokinetics and pharmacodynamic properties.

BigKNY3
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News